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improvement in o s  to 17 months from 13 months. 
It was estimated that 690 patients would need to be 
enrolled. Pre-specified plans were in place to analyze 
the survival data by Eastern Cooperative oncology 
Group (e c o g ) performance status (p s), lactate dehy-
drogenase, and nephrectomy status, using unstratified 
and stratified log-rank tests, the Wilcoxon test, and 
the Cox model. The log-rank test is an appropriate 
test where the ratio of death rates between two treat-
ment arms is constant over time. The Wilcoxon test 
is an appropriate test where the ratio of death rates 
between two treatment arms is not constant over 
time. The latter test places more weight on earlier as 
opposed to late patient events and time points. This 
approach may be more desirable when crossover is 
allowed or when patients are treated with second- or 
third-line agents.
2.  INITIAL RESULTS
Between August 2004 and August 2005, 750 patients 
were accrued from 101 centers. The treatment arms 
were balanced with respect to baseline demographics 
and disease characteristics. With regard to e c o g  p s, 
62% of patients had a p s of 0, and 38% had a p s of 1. 
With regard to the Memorial Sloan–Kettering Can-
cer Center risk classification, 38% had a favourable 
score, 56% had an intermediate score, and 6% were 
scored as poor risk.
Table i summarizes the published results to date, 
which report on p f s and response rates. Patients 
treated with sunitinib had a significantly longer p f s 
than did those treated with interferon: 11 months as 
compared with 5 months, which corresponds to a 
hazard ratio of 0.42 [95% confidence interval (c i ): 
0.32 to 0.54 months; p < 0.001]. Thus, in terms of 
p f s, the study met the primary endpoint. With respect 
to objective response rates, the initial rate reported 
with sunitinib was 31% as compared with 6% with 
interferon (p < 0.001). Health-related quality of life 
(q o l ) was reported to be superior with sunitinib. At 
a s c o  2007, the p f s data were also presented according 
to the Memorial Sloan–Kettering Cancer Center risk 
factors, such that for favourable-risk patients taking 
ABSTRACT
Sunitinib is now a standard first-line therapy for meta-
static clear-cell kidney cancer. This paper focuses on 
interpretation of the overall survival data presented 
at the 2008 annual meeting of the American Society 
of Clinical oncology from the pivotal phase iii trial 
comparing sunitinib with interferon in the first-line 
setting. The previously published progression-free 
survival and response rate data from that study are 
also summarized.
KEY WORDS
Sunitinib, renal cell carcinoma, overall survival
1.  INTRODUCTION
Sunitinib is an oral multi-targeted tyrosine kinase 
inhibitor of vascular endothelial growth factor (v e g f ) 
receptor and platelet-derived growth factor receptor 
that has become a new standard of care in the manage-
ment of metastatic renal cell carcinoma (r c c ). It was 
at the 2006 annual meeting of the American Society 
of Clinical oncology (a s c o ) that Motzer et al. first 
presented the results of a pivotal multicentre phase iii 
trial in metastatic RCC that compared sunitinib with 
interferon alfa. The data were subsequently published 
in January 2007 1,2.
This study by Motzer and colleagues random-
ized previously untreated patients with metastatic 
clear-cell carcinoma to either oral sunitinib (50 mg 
once daily for 4 weeks, followed by a 2-week break) 
or subcutaneous interferon alfa (9×106 IU 3 times 
weekly). The primary endpoint was progression 
free-survival (p f s), and secondary endpoints included 
overall survival (o s ), Response Evaluation Criteria 
in Solid Tumors objective response rates, patient-
reported outcomes, and safety.
From a statistical viewpoint, the study was de-
signed to have 90% power to detect a 35% improve-
ment in p f s to 6.2 months from 4.7 months, using a 
two-sided p value of 0.05. In terms of o s , the study 
was designed to have 85% power to detect a 35% OVERALL SURVIVAL WITH SUNITINIB IN RCC
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sunitinib, p f s was 14.5 months; for intermediate-risk 
patients, 10.6 months; and for poor-risk patients, 3.7 
months, as compared with 7.9 months, 3.8 months, 
and 1.2 months for patients taking interferon 3.
After these results were first presented at a s c o  
2006, sunitinib was very quickly declared the new 
standard of care in this patient population. Sunitinib 
did not receive Health Canada approval until August 
2006, and it then took several months for the indi-
vidual provincial bodies to decide whether to fund 
this agent. Sunitinib is now publicly funded in some 
way in all provinces.
3.  UPDATED DATA
At a s c o  2008, the much-anticipated data related to o s  
were presented orally (abstract 5024 4). despite the 
anticipation for this presentation, clinicians who had 
been treating metastatic r c c  patients during the years 
leading up to June 2008 knew from experience that 
the addition of targeted therapies, and specifically 
sunitinib, into everyday practice prolonged the lives 
of patients with metastatic renal r c c .
Table i summarizes the updated p f s and response 
rate data. objective response rates, as determined by 
independent reviewers, were 39% with sunitinib and 
8% with interferon alfa (p < 0.000001). Median p f s 
had not changed. of the study patients, 14% were still 
on sunitinib, and 2% were still on interferon.
The o s  with sunitinib was 26.4 months (95% c i : 
23 to 32.9 months) as compared with 21.8 months 
(95% c i : 17.9 to 26.9 months) with interferon alfa. 
The log-rank p value was 0.051, and the Wilcoxon p 
value was 0.0128. Because the log-rank p value ex-
ceeded 0.05, some readers may interpret the study as 
negative; however, it is important to remember what 
a “p value” means. A p value of 0.05 represents a 5% 
likelihood of obtaining these results by chance alone. 
A p value of 0.051 represents a 5.1% likelihood of 
obtaining these results by chance alone.
Why was os not more dramatically improved? 
The fact that patients crossed over to sunitinib and 
also that many received second- or third-line therapy 
has to be taken into account. In the sunitinib arm, 
56% of patients received post-study therapy, and in 
the interferon arm, 59% received post-study therapy 
as shown in Table ii. The influence of second-, third-, 
and even fourth-line treatment in metastatic rcc was 
never an issue before the use of targeted therapies, 
but it has now become a major confounder, as 
was seen in the target (Therapeutically Applicable 
Research to Generate Effective Treatments) study 
comparing sorafenib with placebo in the second-line 
setting 5. Crossover from the placebo arm to active 
sorafenib influenced survival, and the os benefit was 
subsequently not statistically significant. It is known 
from the target study that vegf-targeted therapy post 
interferon does prolong survival and thus would 
definitely have influenced the interferon-treated arm 
in the Motzer study.
t a b l e  ii Post-study therapy
   Sunitinib    Interferon    p
    (%)    (%)    Value 
Any further therapy  56  59  n s
Sunitinib  11  33  s s
other v e g f -targeted  33  32  n s
Cytokines  20  13  n s
Inhibitors of mt o r   9  4  n s
Chemotherapy  6  6  n s
n s  = nonsignificant; s s = statistically significant; v e g f  = vascular  
endothelial growth factor; mt o r  = mammalian target of rapamycin.
t a b l e  i  outcomes
Sunitinib     Interferon p Value
Patients (n) 374 337
objective response rates, independent review
[% (95% confidence interval)]
Initial report
31 
(26–36)
6 
(4–9)
0.001 
Updated (a s c o  2008)    39 
(34–44)
8 
(6–12)
0.000001
Progression-free survival
[months (95% confidence interval)]
  Initial report
11 
(10–12)
5 
(4–6)
0.001 
Updated (a s c o  2008)  11 
(11–13)
 5  
(4–6)
0.000001
a s c o  = American Society of Clinical oncology (annual meeting).Wood 
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Because of the influence of post-study treatment, 
the authors also presented the survival data in two 
other ways. The first was to censor the 25 patients 
from the interferon arm who crossed over to the suni-
tinib arm. The second was to exclude all patients who 
received any other post-study treatment. This left 193 
patients in the sunitinib arm with a median o s  of 28.1 
months (95% c i : 19.5 months to not reached), and 
162 patients in the interferon arm with a median o s  
of 14.1 months (95% c i : 9.7 to 21.1 months), log-rank 
p = 0.003. The hazard ratio in this analysis is 0.647 
(95% c i : 0.483 to 0.870). These post hoc analyses 
obviously introduce bias, because there was likely a 
systemic difference in patients who did and who did 
not receive post-study treatment.
Another important component of the study was 
the evaluation of q o l . This evaluation was conducted 
using several q o l  measures, including the Functional 
Assessment of Cancer Therapy–General (f a c t -G), 
the f a c t  Kidney Symptom Index (f k s i, a validated 
15-question symptom index for kidney cancer pa-
tients) and disease-Related Symptoms subscale (a 
9-item subscale of f k s i that pertains more specifically 
to kidney cancer symptoms), the EuroQol-5D utility 
score, and the EuroQol visual analog scale for overall 
health state. This randomized controlled trial is the 
largest in metastatic r c c  comparing patient q o l  in 
two different treatment arms, and the results from 
the q o l  analysis have recently been published 6. The 
primary endpoint focused on disease-related symp-
toms, not treatment-related adverse events; however, 
the overall health questionnaires should also have 
captured treatment-related adverse events. Patients 
on sunitinib have significantly better q o l  as compared 
with patients on interferon. The positive benefit is 
largely attributable to between-group differences 
(that is, sunitinib versus interferon), rather than to 
within-group differences (that is, improvement from 
baseline over time with sunitinib).
4.  DISCUSSION
What is the bottom line?
Canadian medical oncologists are now seeing pa-
tients with metastatic r c c  achieve median survivals of 
more than 2 years. These results are unprecedented. 
Sunitinib produces a p f s benefit over interferon alfa 
in patients with clear-cell metastatic r c c  treated in the 
first-line setting. The primary endpoint was p f s, and 
the study was positive. Although the p value for o s  
in the intent-to-treat analysis was 0.051, the reported 
difference in o s  is quite likely an underestimation 
of the true benefit, given the effect of post-study 
treatment. Such confounders will remain an ongo-
ing problem in metastatic r c c  trials now that several 
agents are active; the likely result is that p f s will be 
the major endpoint in future studies.
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